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Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like 
Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding 
and Specificity  
Adam J. R. Gadd, Francesca Greco, Alexander J. A. Cobb, Alexander D. Edwards 
School of Pharmacy, University of Reading, Whiteknights, Reading, RG6 6AD 
 
Abstract: 
Therapeutic activation of Toll-like receptors (TLR) has potential for cancer immunotherapy, for 
augmenting the activity of anti-tumor monoclonal antibodies (mAbs), and for improved vaccine 
adjuvants. A previous attempt to specifically target TLR agonists to dendritic cells (DC) using mAbs 
failed because conjugation led to non-specific binding and mAbs lost specificity. We demonstrate here 
for the first time the successful conjugation of a small molecule TLR7 agonist to an anti-tumour mAb 
(the anti-hCD 20 rituximab) without compromising antigen specificity. The TLR7 agonist UC-1V150 
was conjugated to rituximab using two conjugation methods and yield, molecular substitution ratio, 
retention of TLR7 activity and specificity of antigen binding were compared. Both conjugation 
methods produced rituximab-UC-1V150 conjugates with UC-1V150 : rituximab ratio ranging from 1:1 
to 3:1 with drug loading quantified by UV spectroscopy and drug substitution ratio verified by MALDI 
TOF mass spectroscopy. The yield of purified conjugates varied with conjugation method, and dropped 
as low as 31% using a method previously described for conjugating UC-1V150 to proteins, where a 
bifunctional crosslinker was firstly reacted with rituximab, and secondly to the TLR7 agonist. We 
therefore developed a direct conjugation method by producing an amine-reactive UV active version of 
UC-1V150, termed NHS:UC-1V150. Direct conjugation with NHS:UC-1V150 was quick and simple 
and gave improved conjugate yields of 65-78%. Rituximab-UC-1V150 conjugates had the expected 
pro-inflammatory activity in vitro (EC50 28-53 nM) with a significantly increased activity over 
unconjugated UC-1V150 (EC50 547 nM). Antigen binding and specificity of the rituxuimab-UC-1V150 
conjugates was retained, and after incubation with human peripheral blood leukocytes, all conjugates 
bound strongly only to CD20-expressing B cells whilst no non-specific binding to CD20-negative cells 
was observed. Selective targeting of Toll-like receptor activation directly within tumors or to DC is 
now feasible. 
 
Keywords: Toll-like receptors, TLR7, tumor immunotherapy, monoclonal antibody 
Introduction 
Therapeutic triggering of TLRs for vaccine and tumor immunotherapy 
Pattern Recognition Receptors (PRRs), such as Toll-like receptors (TLRs), C-type lectins and Nod-
like Receptors (NLRs) are germ line encoded transmembrane proteins pivotal in priming the activation 
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of the adaptive immune system.
1–4
 A range of synthetic and biosynthetic agonists targeting TLR 
activation have been developed for use both as vaccine adjuvants and for cancer immunotherapy. 
5–8
 
TLR agonists range in size from small molecules (imiquimod, guanisine and adenosine analogs) to 
large and complex biomacromolecules such as lipopolysaccharide (LPS), nucleic acids (CpG DNA, 
polyI:C) and lipopeptides (Pam3CSK4). 
Currently of the 5 licensed human vaccine adjuvants, only adjuvant system 04 or AS04, contains a 
TLR agonist. This adjuvant is currently utilized in the human papilloma virus vaccine Cerivax® and 
hepatitis B vaccine FENDrix®.
9,10
 AS04 contains a biosynthetic TLR4 agonist, Monophosphoryl lipid 
A (MPL), added to the conventional adjuvant alum.
11
 In contrast to alum alone, AS04 promotes both 
Th1 and Th2 based responses, rather than a focused Th2 response.
12
 Particulate formulations, such as 
alum, drive immunization by providing a localized deposition of antigen (Ag) but also through 
inflammasome activation via NLRP3 and producing IL-1β and IL-8 promoting Th2 responses.13–15 
Inclusion of the TLR agonist MPL activates additional cytokine responses including IL-12 production, 
that together lead to Th1 activation.
16
  
Aldara is a cream containing the synthetic TLR7 agonist imiquimod, the only other synthetic TLR 
agonist currently licensed for human treatment. Its current applications are topical treatment of actinic 
keratosis, external genital warts and basal cell carcinomas,
17
 demonstrating the broad potential for TLR 
activation for immunotherapeutic treatment of tumors and viral infections. As well as topical 
immunostimulation, imiquimod is also a candidate adjuvant, and has been shown to promote adaptive 
immune responses when applied topically to the site of immunization in studies involving a subunits 
from the parasite Plasmodium falciparum,
18
 as well as improving the efficacy of subunit cancer 
vaccines.
19–21
  
However, immunotherapy with imiquimod is currently limited to topical formulation, as localization 
of potently proinflammatory TLR agonists is vital. Indeed, a major concern with therapeutic use of any 
TLR agonist, which has to date highly limited their clinical use, is that systemic TLR activation can be 
fatal, with toxic shock caused by cytokine syndrome or cytokine storms.
22,23
 Recent efforts have 
therefore focused on reducing and eliminating this systemic toxicity. Typical pro-drug and ante-drug 
formulations have had limited success in imparting tolerability to TLR 7 agonists.
24–26
 Antedrugs are 
active compounds that are metabolically inactivated before entering systemic circulation 
27
. An 
alternative approach is to limit drug availability and localize inflammation by covalent conjugation to 
macromolecular scaffolds such as proteins and polymers, which can effectively limit systemic cytokine 
levels but retain high levels of inflammation at the site of administration.
28
 A further benefit of TLR 
agonist conjugation to proteins is the increase in adjuvant activity when TLR agonists are directly and 
covalently coupled to protein antigen over mixtures of antigen and agonists.
29
 The success of protein 
conjugation of many TLR agonists raises the possibility of using mAbs to deliver TLR agonists. 
 
Rationale for conjugating TLR agonists to monoclonal antibodies. 
We identified three distinct therapeutic applications for TLR agonists conjugated to mAbs: to target 
therapeutic TLR activation to tumors; to promote mAb cytotoxicity; and to deliver TLR agonists to 
antigen presenting cells (APC). 
As various immunomodulatory features of the tumor microenviroment have been identified,
30
 it has 
become increasingly clear that selective triggering of TLRs at the site of a tumor can have both direct 
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and indirect therapeutic benefits. Driven by proven clinical efficacy against basal cell carcinoma,
31
 the 
cancer therapeutic effects of TLR7 agonists such as imiquimod have been extensively characterized, 
and include induction of tumor cell apoptosis.
32–34
 Likewise, the established therapeutic efficacy of 
intravesicular BCG for bladder cancer has led to investigations into replacing this complex biologic 
with one or more synthetic TLR agonist.
7,35
 However, immunotherapy by deliberate TLR activation 
can only safely be achieved by localizing activation and subsequent proinflammatory signals, and so 
tumor targeting is essential. Conjugation to tumor localizing mAbs is a well-established method for 
delivering drugs to solid tumors.
36,37
 
Even without conjugation to cytotoxic drugs, monoclonal antibodies (mAb) are well established 
cancer treatments,
38
 with examples including cytotoxic mAbs targeting CD20 for treatment of 
lymphoma (Rituximab, MabThera), and antibodies targeting Her2 for treatment of Her2+ breast cancer 
(Trastuzumab, Herceptin). However, the efficacy of many mAbs is often limited by poor cytotoxicity, 
and direct tumor cell killing in vivo is also limited by the anti-inflammatory tumour microenviroment.
39
 
Improved tumor killing can be achieved using antibody-drug conjugates (ADC) that deliver cytotoxic 
drugs to tumors cells.
37
 An alternative approach is to improve the cytotoxicity of mAbs. Through Fc 
region binding to FcγR on macrophages, antibody dependent cellular cytotoxicity (ADCC) can directly 
kill antibody-labelled tumor cells, but in the tumor microenvironment inhibitory FcγR dominate 
preventing ADCC. TLR activation at the tumor site is expected to overcome inhibitory FcγR and 
promote ADCC,
40
 and therefore we propose that TLR agonists conjugated to anti-tumor mAbs would 
be expected to have enhanced tumor cytotoxicity. Similarly, TLR triggering is known to augment the 
effects of immunostimulatory mAbs such as anti-CD40, to synergistically promote CD8+ T-cell 
expansion independent of CD4+ T cells, by bypassing the requirement for helper T-cell triggering of 
DC through receptors such as CD40.
41
 Again, the enhancement of antibody activity with TLR 
stimulation suggests that conjugation of TLR agonists to mAbs could be beneficial. 
The only previous report of antibody-TLR agonist conjugates attempted to target a TLR9 agonist 
(CpG oligonucleotide) together with antigen directly to subsets of APC in order to develop improved 
anti-tumor vaccines and promote CTL priming. Antibody mediated targeting of antigen to subsets of 
APC can promote, modulate or inhibit adaptive immune responses,
42
 especially since targeting antigen 
to DC does not inherently lead to the activation required to promote priming of adaptive immunity. 
Unfortunately, the biomacromolecular TLR agonists conjugated to DC-targeting mAbs in this study 
had physicochemical properties that were incompatible with specific antibody targeting, and thus 
antibody specificity was lost even though the conjugates retained proinflammatory activity, and still 
promoted CTL priming and induction of anti-tumor immunity.
43
 TLR9 agonists such as CpG oligos are 
known to be bound by scavenger receptors and promote antigen presentation even in the absence of the 
TLR9 receptor
44
 possibly related to its polyanionic structure.
45
  
This report suggested that alternative TLR conjugation strategies are required to achieve specific 
targeting using antibody conjugation. Other nucleic acid TLR agonists, such as the TLR3 agonist 
polyI:C are highly polyanionic, and synthetic TLR2/4 agonists such as Pam3CSK4 contain a highly 
hydrophobic lipid tail. These classes of agonist are likely to bind to a range of cells and proteins and 
thereby compromise antigen specificity and targeting. In contrast small molecule TLR agonists such as 
the purine analogs or imidazoquinolines that activate TLR7 and/or 8 are far better suited to ADC 
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development as these small molecules lack any of the physicochemical features likely to compromise 
antibody specificity. 
 
This study therefore aimed to investigate the feasibility of targeting small molecule TLR agonists using 
mAbs. To allow rapid evaluation of TLR7 conjugates of a range of different mAbs, we needed to 
develop a rapid, easy to quantify conjugation method that retains the native ability to bind antigens, but 
avoids creating non-specific binding, as well as retaining the characteristic pro-inflammatory TLR 
activation response seen with small molecule TLR7 agonists alone. We therefore synthesised the TLR 
agonist UC-1V150 2 as it has well described protein conjugation methods.
28
 Rituximab was chosen as a 
model anti-cancer mAb because it is well characterized, and allows rapid and simple evaluation of 
specific binding activity using human peripheral blood leukocytes (PBL) which contain both CD20-
expressing cells together with a wide range of different CD20-negative cells. A  simplified protein 
conjugation method was developed to improve yield of TLR7 agonist conjugates. We found for the 
first time that it is possible to make TLR7 agonist-mAb conjugates that both retained proinflammatory 
activity and specific antigen binding.   
 
Results 
 
Synthesis of amine-reactive TLR7 agonist NHS:UC-1V150 
A published method
28
 for conjugating UC-1V150 to proteins by labelling antibody with an amine-
reactive bifunctional linker, followed by addition of TLR7 agonist UC-1V150, was initially tested with 
BSA and mouse and human mAbs. Although this ‘indirect conjugation’ method (Figure 1A) produced 
conjugates with BSA as expected, in contrast this method gave poor conjugate yields with mAbs and a 
significant degree of precipitation was observed suggesting protein denaturation or crosslinking (data 
not shown). This precipitation was highly dependent on the concentration of bifunctional crosslinker 
used (data not shown). An alternative method for conjugating TLR7 agonists to proteins was therefore 
proposed, referred to as ‘direct conjugation’ (Figure 1A) whereby the bifunctional linker (1) was 
reacted firstly with TLR7 agonist UV-1V150 (2) to produce the novel amine reactive TLR7 agonist 
termed NHS:UC-1V150 (3) (Figure 1B), which could then be directly conjugated to free amines on the 
antibody. UC-1V150 was reacted with N-(2,5-dioxopyrrolidin-1-yl)-6-(2-(propan-2-
ylidene)hydrazinyl)nicotinamide using aniline as a catalyst yielding a 96% conversion by 
1
H NMR. 
The resulting product contained UV characteristics of both UC-1V150 λmax 278 nm and N-(2,5-
dioxopyrrolidin-1-yl)-6-(2-(propan-2-ylidene)hydrazinyl)nicotinamide λmax 340 nm shifted from 320 
nm. Monitoring and characterisation of the reaction by NMR indicated that the aldehyde proton δ 9.98 
decreased proportionately with the dimethyl protons of N-(2,5-dioxopyrrolidin-1-yl)-6-(2-(propan-2-
ylidene)hydrazinyl)nicotinamide at δ 2.00. The hydrolysis reaction, yielding the free hydrazine and 
acetone as a byproduct, occurred as a result of the condensation aniline with the aldehyde, indicated by 
the brief formation of the enanime intermediate seen at δ 8.59. The appearance of singlets at δ 11.83 
and 8.16 indicated the formation of the hydrazone. Once the reaction had gone to completion, the 
mixture was stored in a dessicator to avoid hydrolysis, and used without further purification to 
conjugate directly to mAbs (direct method; Figure 1A). 
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Figure 1 Synthesis of NHS:UC-1V150 for direct conjugation to proteins compared to 
conventional indirect conjugation protocol.  
A Reaction schemes for conventional indirect conjugation method (i) vs new direct conjugation 
protocol (ii). B Synthetic scheme used to produce amine reactive TLR7 agonist 3, from bis-functional 
crosslinker 1 and TLR7 agonist UC-1V150 2. C UV spectra of linker 1, TLR7 agonist UC-1V150 2 
and resulting amine reactive TLR7 agonist for direct conjugation NHS:UC-1V150 3.  
  
 
Conjugation of rituximab to TLR7 agonist UC-1V150 
Protein-UC-1V150 conjugates have been described, but conjugation of TLR7 agonists to an antibody 
has not previously been demonstrated. We compared two alternative conjugation methods (Figure 1A), 
and found that both were able to produce TLR 7 antibody conjugates with varying substitution ratios 
(Table 1; Figure 2). Yields varied significantly with the direct conjugation provided improved yields. 
Yields in both methods were substitution ratio dependent suggesting conjugation caused the antibodies 
to become unstable (Figure 2C). In particular protein yield in the indirect conjugation method suffered 
significantly from increasing substitution ratio above 1:1. As intended, the new direct conjugation 
method gave an improved yield of conjugate compared to the indirect method (Figure 2C), and 
precipitation was much reduced (data not shown). 
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Table 1: Conjugation conditions used to produce TLR7 agonist – rituximab conjugates studied 
Sample 
Molar Equivalents 
Rituximab Bifunctional 
crosslinker 1 
UC-1V150  
2 
NHS:UC-1V150  
3 
Indirect (Low MSR) 1 2 8 0 
Indirect (High MSR) 1 5 8 0 
Direct (Low MSR) 1 0 0 10 
Direct (High MSR) 1 0 0 20 
 
 
Figure 2 Characterisation of rituximab-TLR7 agonist conjugates for drug loading and yield of 
purified conjugate. 
A,B UV spectra of rituximab-UC1V150 conjugates produced using indirect (A) and direct protocols 
(B). C Comparison of protein yield after purification for conjugates produced using indirect vs direct 
protocols. D Comparison of mass increase of Rituximab UC-1V150 conjugates observed by MALDI-
TOF/TOF mass spectroscopy vs conjugation ratio calculated from UV spectroscopy (A350 ). 
 
Quantification of TLR7 agonist loading 
After conjugation of the TLR 7 agonists and subsequent separation of conjugated from unconjugated 
drug by size exclusion chromatography, the amount of UC-1V150 covalently coupled to rituximab was 
analysed to determine firstly if conjugation had occurred and secondly to monitor the efficiency and 
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effect of conjugation. UV absorbance (A340) was initially used to determine concentration of the bis-
aryl hydrazone system formed in the conjugation process shown by the altered UV profile of 
conjugates (Figure 2 A and B). The discrepancy in λmax A340 and A280 from the altered UV profiles of 
conjugates produced by direct and indirect methods reflects the variation in yield observed between the 
two conjugation methods (Figure 2 C). Once concentration of the hapten system was known, a mass 
increase over the native protein was calculated and compared to data from MALDI-TOF/TOF mass 
spectroscopy analysis of the samples (Figure 2 D). Both UV and MALDI-TOF/TOF concluded a 
similar mass increase over the native protein indicating conjugation had occurred, substitution ratio was 
scalable and confirming the accuracy of UV absorbance for rapid conjugate analysis. 
 
Pro-inflammatory activity of rituximab TLR 7 agonist conjugates 
Purine analogues have been long known for potent proinflammatory activity, which can be attributed to 
triggering TLR7 and/or TLR8.
46
 Conjugation of these and similar compounds to macromolecules 
including proteins and polymers increase the relative potency of the active compound. We monitored 
IL-12p40 secretion from RAW 264.7 to measure proinflammatory activity of compounds, and 
determine if conjugation of UC-1V150 to antibodies affected proinflammatory responses, and if the 
expected increase in potency was observed. UC-1V150 produced a pro-inflammatory response with an 
EC50 of 547 nM based on IL-12p40 concentration 
(Table 2). Rituximab and mock conjugates without 
UC-1V150 failed to produce a response in this assay 
at the highest concentration tested (Figure 3), 
confirming the mAb and conjugation procedure were 
free from proinflammatory contaminants. Simply 
mixing UC1V150 with rituximab did not alter UC-
1V150 activity (data not shown). Both direct and 
indirect conjugation methods produced conjugates 
that powerfully induced IL-12p40 production, and 
showed greatly increased potency over the 
unconjugated UC-1V150, with potency correlating 
closely to UC-1V150 concentration (Figure 3A and 
B). The low conjugate yields obtained using the 
indirect conjugation method at higher crosslinker 
concentrations provided insufficient quantity of this 
conjugate to fully characterize activity, and therefore 
it was not possible to evaluate the potency in vitro of 
high substitution ratio indirect conjugate. 
 
Figure 3 In vitro analysis of TLR7 agonist activity of Rituximab UC1V150 conjugates. 
IL-12p40 secretion by RAW 264.7 stimulated with conjugates was plotted against drug concentration 
(top) or protein concentration (bottom). 
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Table 2: Influence of Molecular Substitution Ratio of TLR7 agonist - rituximab conjugates on 
proinflammatory activity. 
 
Sample 
Molecular Substitution Ratio (TLR7 
agonist : rituximab) 
IL-12 
stimulation  
EC50 (nM) UV absorbance MALDI-TOF mass 
spectroscopy 
Rituximab 0 0 >2000 ± 0 
Indirect (Low MSR) 1 1.3 28 ± 3 
Indirect (High MSR) 2.1 2.2 Not Tested 
Direct (Low MSR) 1.5 1.1 53 ± 8 
Direct (High MSR) 2.8 2.3 31 ± 3 
UC-1V150 NA NA 547 ± 47 
 
Specific binding to CD20 expressing cells in human peripheral blood leukocytes 
In a previous study significant loss of antibody specificity was observed when TLR agonists were 
conjugated to antibodies that targeted DC.
43
 During the conjugation process, some loss of protein was 
observed with some precipitation visible, especially in conditions where higher concentrations of cross-
linker were used and when the indirect conjugation method was used. This raised concerns over 
possible effects of conjugation on the mAb affecting structure or adding steric bulk. For antibodies this 
could modify or reduce antigen binding or increase non-specific binding.
43
 In order to measure binding 
of TLR-mAb conjugates, a Zenon staining protocol was utilized. This relies on complexing the 
rituximab, rituximab conjugates, or an isotype control, to purified fluorescently labelled Fab fragments 
of secondary antibodies against human IgG prior to addition to PBL. This has the advantage of 
avoiding any requirement to covalently label antibodies and conjugates with fluorophores either before 
or after conjugation, which could affect binding or be affected by conjugation, and simply staining with 
secondary antibodies was also not possible for staining human PBL such as B cells that are already 
coated with human IgG. Leukocytes from human peripheral blood were first stained with APC anti 
CD19 and FITC anti CD3 to identify CD20-positive B cells and CD20-negative T cells respectively 
(Figure 4 A). 
 
After fluorescent complexes of rituximab, rituximab-UC-1V150 conjugates and an isotype matched 
control antibody were formed using the PE Zenon human IgG1 reagent, these were incubated with the 
CD19/CD3 double stained PBL, which were then washed, fixed, and analysed by flow cytometry. 
Unconjugated rituximab and all conjugates stained only CD20-expressing CD19+ B cells strongly and 
specificity and no cross reactivity or increase in background staining was observed on CD3+ cells or 
other CD20-negative PBL (Figure 4 B and C and data not shown). The lowest yielding condition tested 
was the indirect conjugation method with high MSR, as we had expected that this method would be 
most likely to compromise binding and specificity as we assumed that loss of protein stability from 
increased crosslinker concentration and UC-1V150 loading would either reduce antibody binding or 
increase non-specific binding. Surprisingly however, we found that the lowest yielding conjugate tested 
(i.e. indirect method with high MSR) showed the closest level of binding to unconjugated rituximab, 
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better than other conjugates produced in conditions with better yield, suggesting that reduced protein 
yield does not necessarily indicate loss of antibody conformation or activity. None of the conjugates 
tested showed non-specific binding to any CD20-negative cells.  
 
Figure 4 Antigen binding and specificity is maintained by rituximab UC-1V150 conjugates 
Flow cytometric analysis of antibody and conjugate binding to human peripheral blood leukocytes 
was performed using Zenon™ labelling. A Binding of rituximab and conjugates of CD20-expressing B 
cells (CD19+) but not to CD20-negative T cells (CD3+) was observed. B Median fluorescent intensity 
of Zenon staining on gated CD20-expressing B cells (CD19+; left) and CD20-negative T cells (CD3+; 
right) was plotted for rituximab and various UC1V150 conjugates, and isotype control, at the indicated 
concentrations. Inset: equal background staining was observed on CD3+ cells for all antibodies and 
antibody conjugates tested. 
 
Discussion 
TLR7 and TLR8 agonists are potent proinflammatory small molecules with anti-viral and anti-tumor 
activity. However systemic TLR activation can lead to fatal toxic shock, and thus TLR agonists 
conjugated to macromolecules including proteins have been developed that localize inflammation and 
restrict systemic cytokine production. In order to determine if TLR agonists could be targeted 
specifically to tumors or antigen presenting cells using mAbs, we explored whether a small molecule 
TLR7 agonist could be covalently conjugated to the human IgG1 anti-CD20 mAb rituximab, used 
clinically to selectively kill B cells in non-Hodgkins lymphoma. 
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Successful targeting using ADC is dependent on an appropriate and effective conjugation method. A 
previously reported conjugation method referred to here as an indirect conjugation method (Figure 1) 
demonstrated that protein-TLR7 agonist conjugates could be constructed. However, we found that a 
simple modification to the conjugation method (Figure 1) increased compatibility to a wider range of 
proteins by reducing precipitation and thereby increasing conjugate yield for the glycoprotein IgG. We 
believe that protein loss during the indirect method occurs because the intermediate step is a labeled 
protein with pendent hydrazine groups which is then introduced into an acidic pH. Sugars have the 
ability to undergo mutarotation in acidic condition, exposing the normally cyclized aldehyde or ketone. 
At this point cross-linking can occur. Modulation of the molecular abundance of hydrazine containing 
linker used to label IgG help to illustrate this issue. No change in yield was seen when UC-1V150 
concentration was varied but linker concentration kept constant (data not shown). The reaction of 
hydrazines with sugars is a well-known and documented process typically used for the labeling of 
glycoproteins in the presence of oxidizing agents 
47,48
. The modified conjugation method proposed 
removes the possibility of cross-linking. It also improved the control and scalability of substitution 
ratio with minimal effect on yield (Figure 2 C) and reduced the reaction time to 2 h. This method also 
minimizes protein manipulation steps, highly beneficial given the extremely high cost of many 
recombinant or purified proteins in developmental vaccines and also experimental mAbs. Conjugation 
of 100 µg protein or less was achieved with the direct conjugation method (data not shown). Indeed, 
using the previously published indirect conjugation method, the low yields produced with higher 
substitution ratios gave insufficient conjugate to fully characterise in vitro, in contrast to the direct 
method. 
For rapid evaluation of vaccine or tumor immunotherapy conjugates to TLR agonists, a simple method 
of quantifying conjugation efficiency is vital. A benefit of the bifunctional linker chosen is that it is UV 
active, allowing quantification of conjugates using UV spectroscopy. However, UV absorbance and 
extinction coefficients alter after conjugation through the hydrazine (Figure 1C), and the direct 
conjugation method therefore offers the added advantage that the UV active compound is reacted with 
TLR7 agonist drug prior to protein conjugation, and this reaction was monitored precisely to 
completion using NMR. In contrast, the indirect labelling method assumes that for every molecule of 
linker containing the UV active component there is a corresponding molecule of UC-1V150. When the 
linker is reacted first with protein it is not possible to determine by UV alone if any residual unreacted 
linker is present on the protein. We therefore confirmed the molecular substitution ratio using mass 
spectroscopy, which correlated very well with UV quantitation for all conjugates (Tables 2 and S1; 
Figures 2D and S1). 
 
Previous reports have shown that conjugation to proteins and polymers can increase the potency of 
TLR agonists 
28,49
, and this was confirmed with IgG as the macromolecular scaffold. The influence of 
substitution ratio on pro-inflammatory activity has not been reported. From our studies it appears that 
the substitution ratio had relatively minimal effect on cytokine response compared to the initial effect 
of protein conjugation. Although when cytokine production was plotted against molar antibody 
concentration an increase in specific activity was observed with increasing substitution ratio, when 
plotted against the final concentration of UC-1V150 no significant difference in specific activity of 
cytokine production remained (Figure 3). This suggests that although protein conjugation increases 
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potency ~10-fold over UC-1V150 alone, the ratio of conjugation has little further effect on potency. 
The impact of TLR7 activation on anti-tumor antibody efficacy after conjugation remains to be 
established. Anti-tumour mAbs have range of effects including direct cytotoxicity, antibody-dependent 
cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). Since 
activation of TLR is expected to directly influence many of these processes, and the subsequent 
production of proinflammatory cytokines is likely to have further indirect effects on the efficacy of 
anti-tumor mAbs. Likewise, targeting of TLR7 agonists to subsets of DC for vaccine applications is 
likely to have many complex effects. Significant research is now required to fully understand the 
activity of antibody-TLR7-agonist conjugates. Current and planned studies focus on evaluating the 
ADCC and ADCP activity of these conjugates both in vitro and in vivo  
 
For any ADC it is essential that the conjugation process avoids any loss of antibody function, 
especially antigen binding and specificity. Unsurprisingly, UC-1V150 conjugates showed a small 
reduction in binding for CD20, which we assumed was due to the use of a non-specific amine reactive 
conjugation method. This method can potentially label lysine residues in the FAB region leading to 
steric blocking of antigen binding or modulated on and off rates. Interestingly, conjugates produced by 
the indirect method with the highest substitution ratio show the least reduction in CD20 binding similar 
to that of native rituximab, which contrasts to the reduced yield with this method. Further structural and 
cell free antigen binding studies (e.g. surface plasmon resonance) are required to confirm this apparent 
difference between conjugation methods has a significant impact on antibody integrity and binding 
characteristics. Further in vivo targeting studies are also required to confirm specificity of conjugates. 
In future, site-directed conjugation methods could be developed that would avoid nonspecific amine 
targeting.  
 
Previous studies conjugating vaccine antigens to TLR agonists have evaluated the impact of 
conjugation on protein integrity. Covalent conjugation of small molecule TLR agonists to HIV GAG 
protein has been shown previously to elicit a broad-spectrum adaptive immune response 
50
, as well as 
using small peptide sequences covalently conjugated to TLR agonists 
51
, suggesting that TLR 
conjugation does not significantly compromise protein structure and antigenicity. Recent data suggest 
that even under high labeling ratios important structural epitopes remain intact 
52
. The presence of a 
lysine residue in the epitope determined if conjugation could occur at that site, if conjugation did occur, 
antibodies for that epitope had a reduced binding affinity, but importantly other epitopes remained 
accessible indicating limited global structural changes after conjugation 
52
. Thus although the 
conjugation of TLR agonists to proteins using free amine reactive linkers lacks site specificity, the 
likelihood of structural changes or epitope masking is not expected to be a major problem. Indeed, 
amine-reactive conjugation to mAbs has been widely used as an effective and established strategy for 
ADC 
53
 
 
Conclusion 
We demonstrate for the first time that small molecule TLR agonists can be coupled to a therapeutic 
mAb whilst retaining antigen binding, specificity, and TLR stimulatory activity. Previous methods for 
conjugation UC-1V150 to proteins were modified to improve compatibility with glycoproteins such as 
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therapeutic mAbs. The direct conjugation method improves protein yield, but also reduces protein 
handling times and is therefore ideal for rapid screening of different therapeutic antibodies. We 
confirmed UV quantification accurately correlated with mass increase again allowing rapid and high 
throughput analysis of conjugates. Using mAbs as a macromolecular scaffold to limit systemic TLR 
activation, combined with tumor or APC targeting, and enhanced TLR-stimulatory potency following 
protein conjugation, overall offers great potential in three distinct therapeutic areas. Tumor 
immunotherapy can be improved either by direct therapeutic targeting of TLR activation to the tumor, 
or by indirectly improving cytotoxicity of anti-tumor antibodies, and finally improved vaccine 
adjuvants can now be developed by targeting TLR activation to selected APC subsets.  
Experimental Section 
Materials 
Empty spin columns and Nunc® Maxisorp ELISA plates were purchased from Fisher scientific 
(Loughbrough, UK). Spehadex™ G50 superfine was purchased from GE Healthcare (UK). PBS, FBS, 
RPMI and Zenon™ PE were purchased from Life Technology (Paisley, UK). 2-mercaptoethanol, 
EDTA, Bradford reagent, NaN3, Streptavidin alkaline phosphatase conjugate, Sigmafast pNPP and 
Human IgG1 kappa isotype control were all purchased from Sigma Aldrich (Gilford, UK). N-(2,5-
dioxopyrrolidin-1-yl)-6-(2-(propan-2-ylidene)hydrazinyl)nicotinamide was purchased from Solulink 
(San Diago, USA). Red cell lysis buffer, staining buffer, fixing buffer, ELISA and flow cytometer 
antibodies were purchased from eBioscience (Hatfield, UK). Cellstar 96 well tissue culture plates were 
purchased from Greiner (Stonehouse, UK). LAL chromogenic endpoint assay was purchased from 
Hycult biotech (Uden, Netherlands). Rituximab (MabThera, Roche) was obtained from the Royal 
Berkshire Hospital (Reading, UK). 
Synthesis of 4-((6-amino-2-(2-methoxyethoxy)-8-oxo-7,8-dihydro-9H-purin-9-
yl)methyl)benzaldehyde: UC-1V150 
Compound 2, UC-1V150 was synthesized according to previously reported procedure
28
 and retrieved 
as an off-white solid. 
1
H NMR – ((CD3)2SO, 400 MHz): δ 10.06 (1H, s), 9.98 (1H, s), 7.88 (2H, d, J 8.4), 7.49 (2H, d, J  
8.4), 6.58 (2H, s), 4.97 (2H, s), 4.27 (2H, t, J 4.4), 3.58 (2H, t, J 4.4), 3.26 (3H, s).  
13
C NMR ((CD3)2SO, 100 MHz): δ 192.6, 159.7, 152.3, 149.1, 147.8, 143.8, 135.3, 132.5, 129.8, 
128.2, 127.9, 98.59, 70.17, 65.2, 58.0, 42.2  
HRMS (ESI) calculated for C16H18N5O4
+
 (MH
+
) 344.1353. Found 344.1353 
N-(2,5-dioxopyrrolidin-1-yl)-6-(2-(propan-2-ylidene)hydrazinyl)nicotinamide 1 
1
H NMR ((CD3)2SO, 400 MHz): δ 10.39 (1H, s), 8.77 (1H, d J 2.4), 8.12 (1H, dd J 8.8, 2.4), 7.18 
(1H, d J 8.8), 2.89 (4H, s), 2.01 (3H, s), 1.99 (3H, s) 
Synthesis of 2,5-dioxopyrrolidin-1-yl (E)-6-(2-(4-((6-amino-2-(2-methoxyethoxy)-8-oxo-7,8-
dihydro-9H-purin-9-yl)methyl)benzylidene)hydrazinyl)nicotinate 3 
N-(2,5-dioxopyrrolidin-1-yl)-6-(2-(propan-2-ylidene)hydrazinyl)nicotinamide (1 mg, 3.5x10
-6
 mol) 
was dissolved in (CD3)2SO (450 μL) with UC-1V150 (1.2 mg, 3.5x10
-6
 mol) and PhNH2 (5 mMol final 
conc, 200 μg). The mixture was monitored by NMR until the depletion of the peak at δ 9.98 and 
appearance of δ 11.83. The compound was used without further purification. 
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1
H NMR (crude) ((CD3)2SO, 400 MHz): δ 11.83 (1H, s), 10.08 (1H, s), 8.81 (1H, d, J 2.4), 8.20 (1H, 
dd, J 8.8,  2.3), 8.16 (1H, s),  7.71 (2H, d, J 8.2) 7.37 (d, 2H, J = 8.2), 6.97 (1H, d, J  7.7), 6.54 (2H, s), 
4.90 (2H, s),  4.27 (2H, t,  J = 4.7), 3.59, (2H, t, J = 4.7), 3.28 (s, 3H), 2.89 (s, 4H).  
13
C NMR ((CD3)2SO, 175 MHz): 179.7, 170.7, 160.9, 159.9, 152.3, 151.9, 149.1, 147.8, 143.3, 
142.9, 139.2, 138.7, 133.7, 132.6, 128.0, 126.9, 110.8, 98.5, 70.3, 65.4, 58.1, 42.3, 30.7, 29.6, 27.4, 
25.5 
NMR and mass spectra are reported in supplementary data. 
 
Conjugation of 2,5-dioxopyrrolidin-1-yl (E)-6-(2-(4-((6-amino-2-(2-methoxyethoxy)-8-oxo-7,8-
dihydro-9H-purin-9-yl)methyl)benzylidene)hydrazinyl)nicotinate to rituximab. 
Preparation and equilibration of size exclusion spin columns 
Sephadex® G50 superfine (1 g) was added to PBS (20 mL, varying pH) and allowed to hydrate for at 
least 4 h, typically overnight. The supernatant was removed and a further 1 mL of PBS was added and 
mixed to allow manipulation by pipette. 700 μL of the solution was transferred to a spin column, which 
was placed in a standard 1.5 mL eppendorf and centrifuged at 200 G for 1 minute. A further 100 μL of 
PBS was loaded onto the Sephadex bed then centrifuged for 1 minute at 200 G. A further 100 μL 
aliquot was loaded and centrifuged for 2 minutes at 200 G.  The spin column was transferred into a new 
eppendorf and used subsequently. The efficiency of removal of UC-1V150 and bifunctional linker from 
mAb with these micro size exclusion columns was determined, and found that mAb eluted exclusively 
in the column void volume, fraction 1. Residual DMSO was not observed until fraction 3 and that no 
trace of unconjugated small molecules eluted in fractions 1-5 when using 100 μL eluent indicating 
efficient separation of mAb and unconjugated active compound. 
Direct conjugation of UC-1V150 to rituximab to produce TLR7 agonist-rituximab conjugates 
Rituximab (100 μg, 6.6x10-10 mol) was desalted in to PBS (pH 9) using a pre-equilibrated size 
exclusion spin column. The solution was briefly vortexed before adding a 10x molar excess of 3 (1 μL) 
and vortexed before incubating at room temperature for 2 h. To modulate the labeling ratio, eg to 
achieve a 2:1 TLR agonist-rituximab conjugate a 20x molar excess of 3 (2 μL) was added. The mixture 
was vortexed before desalting as previously described into PBS (pH 7.2) for subsequent 
characterisation. 
Indirect conjugation of NHS:UC-1V150 to achieve a 1:1 TLR7 agonist – rituximab conjugate 
Rituximab (100 μg, 6.6x10-10 mol) was desalted in to PBS (pH 9) using a pre-equilibrated size 
exclusion spin column. The solution was briefly vortexed before adding a 2x molar excess of (2) 
predissolved in DMSO to a final concentration 1 mg/mL. The mixture was incubated for 2 h at room 
temperature before vortexing and desalting into PBS (pH 6).  The solution was vortexed and an 8x 
molar excess of UC-1V150 predissolved in DMSO (1 mg/mL) was added mixed and incubated at room 
temperature for a minimum of 12 h. The solution was vortexed before desalting as previously described 
into PBS (pH 7.2) for subsequent characterization.  
Assessment of TLR7 agonist loading ratio 
To calculate the loading ratio of TLR 7 agonist on rituximab, first the concentration of nicotinate 3 in 
the sample was calculated by A340 then divided by the total protein concentration determined by 
Bradford assay. UV/vis absorbance spectrum was recorded between the wavelength of 200-700 nm at 5 
nm increments on a Biotek Take 3 system (Potton, UK). Absorbance readings were corrected to a 
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pathlength of 1 cm using internal path length determination. A standard curve was produced by serial 
dilution of 3 and A340 plotted to produce a formula y = 0.0038x - 0.0182. A UV/Vis spectrum of 
conjugates was recorded and the formula used to determine TLR agonist concentration in the 
conjugate. Since 3 is UV active and has λmax at 274 and 340 nm, A280 cannot be used to determine 
protein concentration. A Bradford assay was therefore used according to the manufactures instructions 
for 96 well assays (Sigma Aldrich). The mass of rituximab and the subsequent mass increase of the 
conjugates was monitored using a Brukner Ultraflex MALDI TOF/TOF mass spectrometer in high 
range mode, 25 kV 350 ns ion pulse with BSA as a calibration (Table S1 and Figure S1). 
Endotoxin contamination 
Endotoxin is a component of bacterial cell walls with potent inflammatory response through TLR4, and 
is also a common laboratory contaminant. Synthesis and conjugation was completed in sterile 
environment and only endotoxin free reagents used. To confirm the absence of endotoxin 
contamination, a LAL assay was used to quantify the amount of soluble endotoxin in all reagents. 
Endotoxin quantification was performed according to manufacturer’s instruction (Hycult, Netherlands), 
and all conjugates tested were below the limit of detection of 0.08 EU/mL. 
Stimulation of RAW264.7 macrophages with rituximab-TLR7 agonist conjugates 
RAW cells were maintained and subcultured as described in ATCC procedures for this cell line. 
Stimulation assays were performed in tissue culture grade 96 well plates. Conjugates were diluted 
serially 1:2 (100 μL final volume) in complete media (RPMI 1640, 10 % FBS, 0.05 mM 2-ME) then 
2x10
6
 cells/mL freshly passaged cells were added in 100 μL to give a final volume of 200 μL. Plates 
were incubated for 24 h before the analysis of supernatants for pro-inflammatory cytokines. IL-12p40 
concentrations in supernatants of RAW 264.7 stimulation assays were determined by sandwich ELISA 
following a standard sandwich ELISA protocol. Nunc maxisorp 96 well ELISA plates were coated 
overnight with IL-12p40 capture antibody (C15.6) at 2 μg/mL in carbonate buffer (pH 9.6, 50 μL per 
well), followed by 2 h with 200 μL per well block buffer (PBS, 2.5 v/v% FBS, 0.02 w/v% NaN3). 100 
μL per well detection antibody (C17.8) at 1 μg/mL in block buffer was added. Stimulated RAW264.7 
supernatants were diluted 1:7.5 in block buffer, and compared to 1:2 dilution of recombinant IL-12p40 
standards with a top concentration of 10 ng/mL in block buffer, with 150 μL sample per well. 
Extravidin alkaline phosphatase conjugate was prepared 3:10,000 dilution in PBS. Sigmafast pNPP 
substrate was prepared according to manufactures instructions.  
Determination of specific binding to human CD20 in human peripheral blood leukocytes 
Peripheral blood from healthy donors was collected in lithium heparin vacutainers. Erythrocytes were 
lysed by the addition of red cell lysis buffer and incubation at room temperature for 10 minutes before 
centrifuging at 200 G for 5 minutes. The supernatant was removed and the pellet resuspended in red 
cell lysis buffer. After washing, PBL were resuspended in staining buffer at 1x10
7
 cells/mL. Zenon™ 
PE human FC labeling kit was used to fluorescently label rituximab, rituximab-UC-1V150 conjugates 
and an isotype control following manufactures guidelines (Life Technologies). Cells were first stained 
with APC-anti-human-CD19 and FITC anti-human-CD3, and subsequently Zenon-labelled antibodies 
and conjugates were added and incubated for 30 mins on ice before fixing in fixation buffer. Fixed 
samples were analyzed on a BD Accuri™ C6 flow cytometer (Oxford, UK) and data analysed using 
FlowJo (Ashland, USA).  
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